This is a news story, published by Gizmodo, that relates primarily to Hims & Hers news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
other weight loss medication offerings. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss medication news, prescription news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
popular weight loss drugsGizmodo
•71% Informative
Hims & Hers is now offering customers a compounded version of semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy .
The company’s shares soared over 30% during Monday trading following the news.
The announcement comes as skyrocketing demand for GLP-1 medications has made them harder to access.
In January , the FDA said it had received adverse reports from patients taking a compounded drug.
VR Score
58
Informative language
51
Neutral language
27
Article tone
formal
Language
English
Language complexity
52
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Affiliate links
no affiliate links